By Jacob GoldsteinPfizer is rummaging through the cabinets of its R&D unit, selling off experimental drugs that don’t fit with the company’s recent focus on fewer diseases. The plan is to sell to other companies about 100 experimental drugs that treat conditions such as obesity and high cholesterol, Bloomberg reports. The move is a logical extension of the company抯 announcement last fall that it was focusing on a few therapeutic areas and largely abandoning research into heart disease, anemia, osteoporosis, liver disease,oakley sunglasses frogskins, muscle disease, obesity, and peripheral artery disease.It also fits with the company抯 plan, announced yesterday,ghd straighteners, to lay off 800 researchers this year.“We haven抰 taken any hit on productivity,” said Pfizer R&D honcho Martin Mackay, according to Bloomberg. “We haven抰 missed any milestones. We are keeping the organization fully focused on the work we have to do.”And,roger vivier flats, in yet another sign that selling drugs has a lot to do with selling anything else, Pfizer said this morning that Stephen W. Sanger is joining the company抯 board of directors. Sanger was CEO of General Mills from ?95 until ?07 and is currently a director of Wells Fargo.

meC BYC iuu

nike slovensko ceR JAY gyc

mulberry sale ecX AZE fqc